Zynerba Pharmaceuticals, Inc. (ZYNE)
(Delayed Data from NSDQ)
$11.45 USD
+0.35 (3.15%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.45 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[ZYNE]
Reports for Purchase
Showing records 1 - 20 ( 119 total )
Industry: Medical - Generic Drugs
Zynerba Sold Given Market Liquidity Constraints; We Project CVR Upside From Here, But Downgrade to Neutral on Deal
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Generic Drugs
Industry: Medical - Generic Drugs
2H23 FXS Pivotal Data on Track; Taking Autism Forward Into Phase 3; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Generic Drugs
3Q21: Zygel FXS Phase 3 Data Still Expected 2H23; Color on Other Potential Indications by Year End; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Generic Drugs
Industry: Medical - Generic Drugs
Zygel Enriched FXS Phase 3 Re-do Started; Other Indication Clarity By Year-End
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Generic Drugs
Industry: Medical - Generic Drugs
Industry: Medical - Generic Drugs
FXS Phase 3 Redo Design Suggests FDA Accommodating; 2023 Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Generic Drugs
Industry: Medical - Generic Drugs
4Q20 Recap - FDA Meeting for FXS in 1H21; Cash Runway Extended
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Industry: Medical - Generic Drugs
Industry: Medical - Generic Drugs
FXS Delayed Over Two Years as FDA Rebuffs Long-Shot Bid for NDA Filing on Post Hoc Data; PT Lower to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Generic Drugs
Industry: Medical - Generic Drugs
Industry: Medical - Generic Drugs
3Q20: Crucial Clarity From FDA in 4Q on Zygel Path Forward in FXS; Could Be Major Upside Surprise; Reiterate
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Generic Drugs
3Q20 Recap - FDA Update (FXS) Looms in 4Q20 as Significant Catalyst
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Industry: Medical - Generic Drugs
2Q20: Potential Near-Term Clarity for Zygel Path Forward in FXS and DEE; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O